Polio
58
1
2
43
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Published Results
11 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 58 trials
100.0%
+13.5% vs benchmark
50%
29 trials in Phase 3/4
26%
11 of 43 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 43 completed trials
Clinical Trials (58)
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine
Study of Concomitant Administration of the sIPV and DTaP or MMR
A Tool Kit to Improve Vaccine Confidence in the Philippines
Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Phase IV Study of Concomitant Administration of the sIPV and HepA
Community Engagement and Conditional Incentives to Accelerate Polio
Evaluation of Fatigue Severity, Mood, and Quality of Life in Post-Polio Syndrome
Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally
Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV
Immunogenicity of After Primary Immunization and Booster Immunization of sIPV
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Effect of Digital Payment to Campaign Health Workers on Vaccination Coverage
Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China
To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan
Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant